Delayed intervention may combat overtreatment of prostate cancer, study suggests

February 28, 2006

Delayed surgical treatment for patients with small, low-grade prostate cancer tumors was not associated with lowered curability, according to a study in the March 1 issue of the Journal of the National Cancer Institute.

Men who receive screening with prostate specific antigen (PSA) for prostate cancer are diagnosed about 10 years earlier than men who do not receive PSA screening. Early diagnosis may have contributed to a decrease in prostate cancer mortality, but it may also result in diagnoses of cancer that would never have become clinically apparent. Some researchers have suggested that active surveillance programs (i.e., delayed treatment) might decrease overtreatment for men diagnosed with prostate cancer on the basis of PSA screening, but there are concerns that surveillance could lead to increases in inoperable tumors.

H. Ballentine Carter, M.D., and colleagues at the Johns Hopkins University School of Medicine in Baltimore, enrolled a group of 320 men suspected of having small, lower-grade prostate cancer in an active surveillance program, 38 of whom underwent delayed surgical intervention after a median of 26.5 months between 1995 and February 1, 2005. Outcomes in this cohort of 38 men were compared with those of a group of 150 patients given immediate surgical treatment after a median of 3 months.

Risks of noncurable prostate cancer, as defined by having a less than 75% chance of remaining disease-free 10 years after surgery, were equivalent in men who received immediate or delayed surgical treatment. Variables associated with risk of noncurable prostate cancer included age at time of diagnosis, PSA level, and PSA density (i.e., PSA level divided by prostate volume). The authors suggest that men diagnosed with early-stage, low-grade prostate cancer have an alternative to immediate surgical treatment, because these men have an equivalent risk of noncurable prostate cancer if surgery is delayed for up to two years after diagnosis, with the use of active surveillance as a management program.

The authors write, "Expectant management with curative intent appears to be a safe alternative to immediate treatment for a carefully selected group of patients with small-volume, lower-grade prostate cancer."
-end-
Contact: Eric Vohr, 410-404-7530, evohr1@jhmi.edu

Citation: Warlick C, Trock BJ, Landis P, Epstein JI, and Carter HB. Delayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome. J Natl Cancer Inst 2006; 98: 355-357.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.